In vitro antineoplastic activity of a novel lanthionine-containing peptide

Clinical Cancer Research

Volumn 3, Issue 8, 1997, Pages 1323-1330

  Zheng, Hua ^a   Fink, Daniel ^a   Li, Haitao ^b   Jiang, Xiaohui ^b   Aebi, Stefan ^a   Law, Ping ^b   Goodman, Murray ^b   Howell, Stephen B ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLCYSTEINYLTHREONINAMIDE 2,6 DISULFIDE; LAN 7; LANTIBIOTIC; OCTREOTIDE; OLIGOPEPTIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL SURVIVAL; COLORECTAL NEOPLASMS; ENDOMETRIAL NEOPLASMS; FEMALE; HEAD AND NECK NEOPLASMS; HEMATOPOIETIC STEM CELLS; HUMANS; KINETICS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PEPTIDES, CYCLIC; SOMATOSTATIN; TUMOR CELLS, CULTURED;

EID: 0030854819     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Lewin, M. J. M. The somatostatin receptor in the GI tract. Annu. Rev. Physiol., 54: 455-468, 1992.
2. Reisine, T. Somatostatin receptors. Am. J. Physiol., 269: G813-G820, 1995.
3. Law, S. F., Woulfe, D., and Reisine, T. Somatostatin receptor activation of cellular effector systems. Cell. Signalling, 7: 1-8, 1995.
4. Bauer, W., Briner, U., Doepfner, W., Haller, R., Huguenin, R., Marbach, P., Petcher, T. J., and Pless, J. SMS-201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci., 21: 1133-1140, 1982.
5. Anthony, L., Johnson, D., Hande, K., Shaffer, M., Winn, S., Krozely, M., and Oates, J. Somatostatin analogue Phase I trials in neuroendocrine neoplasms. Acta Oncol., 32: 217-223, 1993.
6. Setyono-Han, B., Henkelman, M. S., Foekens, J. A., and Klijn, J. G. M. Direct inhibility effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res., 47: 1566-1570, 1987.
7. Liebow, C., Reilly, M., Serrano, M., and Schally, A. V. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc. Natl. Acad. Sci. USA, 86: 2003-2007, 1989.
8. Bogden, A. E., Taylor, J. E., Moreau, J. P., Coy, D. H., and LePage, D. J. Response of human lung tumor xenografts to treatment with a somatostatin analogue (somatuline). Cancer Res., 50: 4360-4365, 1990.
9. Keri, G., Mezo, I., Nadasz, Z., Horvath, A., Idei, M., Vantus, T., Balogh, A., Bokonyi, G., Bajor, T., Teplan, I., Tams, J., Mak, M., Horvath, J., and Csuka, O. Structure activity relationship studies of novel somatostatin analogs with antitumor activity. Pept. Res, 6: 281-288, 1993.
10. Keri, G., Mezo, I., Horvath, A., Vadasz, Z., Balogh, A., Idei, M., Vantus, T., Teplan, I., Mak, M., Horvath, J., Pal, K., and Csuka, O. Novel somatostatin analogs with tyrosine kinase inhibitory and antitumor activity. Biochem. Biophys. Res. Commun., 191: 681-687, 1993.
11. Keri, G., Erchegyi, J., Horvath, A., Mezo, I., Idei, M., Vantus, T., Balogh, A., Vadasz, Z., Bokonyi, G., Seprodi, J., Teplan, I., Csuka, O., Tejeda, M., Gaal, D. Szegedi, Z., Szende, B., Roze, C., Kalthoff, H., and Ullrich, A. A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc. Natl. Acad. Sci. USA, 93: 12513-12518, 1996.
12. Disaia, P. J., Sinkovics, J. G., Rutledge, F. N., and Smith, J. P. Cell-mediated immunity to human malignant cells. Am. J. Obstet. Gynecol., 114: 979-989, 1972.
13. Krause, C. J., Carey, T. E., Ott, R. W., Hurbis, C., McClatchey, K. D., and Regezi, J. A. Human squamous cell carcinoma: establishment and characterization of new permanent cells lines. Arch. Otolaryngol., 107: 703-710, 1981.
14. Koi, M., Umar, A., Chaudan, D. P., Cherian, S. P., Carethers, J. M., Kunkel, T. A., and Boland, C. R. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitroguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res., 54: 4308-4312, 1994.
15. Umar, A., Boyer, J. C., Thomas, D. C., Nguyen, D. C., Risinger, J. I., Boyd, J., Ionov, Y., Perucho, M., and Kunkel, T. A. Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J. Biol. Chem., 269: 14367-14370, 1994.
16. Choi, K., Chen, C., Kriegler, M., and Roninson, I. An altered pattern of cross-resistance in multi-drug resistant human cell results from spontaneous mutation in the mdr1 (P-glycoprotein) gene. Cell, 53: 519-529, 1989.
17. Kemp, L. M., Sedwick, S. G., and Jeggo, P. A. X-ray sensitive mutants of Chinese hamster ovary cells defective in double-strand break rejoining. Mutat. Res., 132: 189-196, 1984.
18. Taccioloi, G., Gottlieb, T. M., Blunt, T., Priestly, A., Demengeot, J., Mizuta, R., Lehmann, A., Alt, F. W., Jackson, S. P., and Jeggo, P. A. Ku80: product of the XRCC5 gene and its role in DNA repair and V(D)J recombination. Science (Washington DC), 265: 1442-1445, 1994.
19. Ross, G. M., Eady, J. J., Mithal, N. P., Bush, C., Steel, G. G., Jeggo, P. A., and McMillan, T. J. DNA strand break rejoining defect in xrs-6 is complemented by transfection with the human Ku80 gene. Cancer Res., 55: 1235-1238, 1995.
20. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., Gray-Goodrich, M., Campbell, H., Mayo, J., and Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst., 83: 757-765, 1991.
21. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst., 82: 1107-1112, 1990.
22. Picketts, D. J., Mayanil, C. S., and Gupta, R. S. Molecular cloning of a Chinese hamster mitochondrial related to the "chaperonin" family of bacterial and proteins. J. Biol. Chem., 264: 12001-12008, 1989.
23. McGahon, A. J., Martin, S. J., Bissonnette, R. P., Mahboubi, A., Shi, Y., Mogil, R., Nishioka, W. K., and Green, D. R. The end of the cell line: methods tor the study of apoptosis in vitro. In: L. M. Schwartz and B. A. Osborne (eds.), Methods in Cell Biology, pp. 153-181, 1995.
24. Gercel-Taylor, C., Gibb, R. K., and Taylor, D. D. Effect of all-trans retinoic acid on the apoptosis induced by cisplatin and taxol in ovarian cancer cell lines. Proc. Am. Assoc. Cancer Res., 37: 23, 1996.
25. Dean, P. N., and Jett, J. H. Mathematical analysis of DNA distributions derived from flow microfluorometry. J. Cell Biol., 60: 523-527, 1974.
26. Lane, T. A., Law, P., Maruyama, M., Young, D., Burgess, J., Mullen, M., Mealiffe, M., Terstappen, L. W., Hardwick, A., Moubayed, M., Oldham, F., Corringham, R. E. T., and Ho., A. D. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood, 85: 275-282, 1995.
27. Jozan, S., Lafon, C., Mathieu, C., Caliaro, M. J., Barboule, N., Bugat, R., and Valette, A. Enhancement of cisplatin cytotoxicity by all trans retinoic acid in a human ovarian carcinoma cell line (OVCCRI) is characterized by apoptosis. Proc. Am. Assoc. Cancer Res., 37: 414, 1996.
28. Aebi, S. P., Kurdi-Haidar, B., Gordon, R., Cenni, B., Zheng, H., Christen, R., Boland, C. R., Koi, M., Fishel, R., and Howell, S. B. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56: 3087-3090, 1996.
29. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehme, A., Christen, R., and Howell, S. The role of DNA mismatch repair in platinum drug resistance. Cancer Res., 56: 4881-4886, 1996.
30. Kat, A., Thilly, W. G., Fang, W., Longley, M. J., Li, G., and Modrich, P. An alkylation-toleration, mutator human cell line is deficient in strand-specific mismatch repair. Proc. Natl. Acad. Sci. USA, 90: 6424-6428, 1995.
31. Aquilina, G., Biondo, R., Dogliotti, E., and Bignami, M. Genetic consequences of tolerance to methylation DNA damage in mammalian cells. Carcinogenesis (Lond.), 14: 2097-2103, 1993.
32. Boubnov, N. V., Hall, K. T., Wills, Z., Lee, S. E., He, D. M., Benjamin, D. M., Pulaski, C. R., Band, H., Reeves, W., and Hendrickson, E. A. Complementation of the ionizing radiation sensitivity DNA end binding, and V(D)J recombination defects of double-strand break repair mutants by the p86 Ku autoantigen. Proc. Natl. Acad. Sci. USA, 92: 890-894, 1995.
33. Sharma, R. C., Inoue, S., Roitelman, J., Schimke, R. T., and Simoni, R. D. Peptide transport by the multidrug resistance pump. J. Biol. Chem., 267: 5731-5734, 1992.
34. Euda, K., Cardarelli, C., Gottesman, M. M., and Pastan, I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. USA, 84: 3004-3008, 1987.
35. Shalinsky, D. R., Heath, D. D., Jekunen, A. P., Alcaraz, J. E., and Howell, S. B. Selective modulation of vinblastine sensitivity by 1,9-dideoxyforskolin and related diterpenes in multidrug resistant tumor cells. Br. J. Cancer, 67: 471-479, 1993.
36. Keri, G., Mezo, I., Horvath, A., Vadasz, Z., Balogh, A., Idei, M., Vantus, T., Teplan, I., Horvath, J., and Szende, B. Novel somatostatin analogs with antitumor activity. In: N. Yanaihara (ed.), Peptide Chemistry 1992, pp. 334-336. Leiden: ESCOM Science Publishers BV, 1993.
37. Fraser, A., and Evan, G. A license to kill. Cell, 85: 781-784, 1996.
38. Buscail, L., Esteve, J-P., Saint-Laurent, N., Bertrand, V., Reisine, T., O'Carroll, A-M., Bells, G. I., Schally, A. V., Vaysse, N., and Susini, C. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc. Natl. Acad. Sci. USA, 92: 1580-1584, 1995.
39. Rauly, I., Saint-Laurent, N., Delesque, N., Buscail, L., Esteve, J. P., Vaysse, N., Susini, C. Induction of a negative autocrine loop by expression of Sst2 somatostatin receptor in NIH 3T3 cells. J. Clin. Invest., 97: 1874-1881, 1996.
40. Reubi, J. C., Schaer, J. C., Waser, B., and Mengod, G. Expression and localization of somatostatin receptor SSTR2 and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res., 54: 3455-3459, 1994.
41. Reeves, W. H. Antibodies to the P70/P80 (Ku) antigens in systemic lupus erythematosus. Annu. Rev. Physiol., 54: 455-468, 1992.
42. Lees-Miller, S. P., Sakaguchi, K., Ullrich, S. J., Appella, E., and Anderson, C. W. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol. Cell. Biol., 12: 5041-5049, 1992.
43. Bannister, A. J., Gottlieb, T. M., Kouzarides, T., and Jackson, S. P. c-Jun is phosphorylated by the DNA-dependent protein kinase in vitro: definition ot the minimal kinase recognition motif. Nucleic Acids Res., 12: 1289-1295, 1993.
44. Le Romancer, M., Cherifi, Y., Reyl-Desmars, F., and Lewin, M. J. Somastostatin specifically binds p86 subunit of the autoantigen Ku. C. R. Acad. Sci., 316: 1283-1285, 1993.
45. Le Romancer, M., Reyl-Desmars, F., Cherifi, Y., Pigeon, C., Bottari, S., Meyer, O., and Lewin, M. J. M. The 86-kDa subunit of autoantigen Ku is a somatostatin receptor regulating protein phosphatase-2A activity. J. Biol. Chem., 269: 17464-17468, 1994.
46. Choi, K., Chen, C., Kriegler, M., and Roninson, I. B. An altered pattern of cross-resistance in multi-drug resistant human cells results from spontaneous mutation in the MDR1 (P-elycoprotein) gene. Cell, 53: 519-529, 1988.